Noninteraction of temazepam and cimetidine

D. J. Greenblatt, D. R. Abernethy, M. Divoll, A. Locniskar, J. S. Harmatz, R. I. Shader

Research output: Contribution to journalArticle

Abstract

The possible kinetic interaction of the hypnotic temazepam and the H2-receptor antagonist cimetidine was evaluated. Nine healthy male and female volunteers received a 30-mg oral dose of temazepam on two occasions in random sequence, separated by at least 1 week. On one occasion, temazepam was given in the otherwise drug-free state; on the other, temazepam was given with concurrent administration of cimetidine, 300 mg every 6 h. Mean pharmacokinetic parameters for temazepam in control versus cimetidine trials were: peak plasma concentration, 560 versus 498 ng/mL; time of peak concentration, 2.0 versus 2.1 h after the dose; volume of distribution, 1.30 versus 1.39 L/kg; elimination half-life, 9.9 versus 11.4 h; total clearance, 1.59 versus 1.60 mL/min/kg; free fraction of temazepam in plasma, 4.1 versus 3.8% unbound. Cimetidine has been shown to reduce the metabolic clearance of the benzodiazepines that are biotransformed by oxidative mechanisms. Temazepam, transformed by conjugation, appears unaffected by the coadministration of cimetidine.

Original languageEnglish (US)
Pages (from-to)399-401
Number of pages3
JournalJournal of Pharmaceutical Sciences
Volume73
Issue number3
DOIs
StatePublished - 1984
Externally publishedYes

Fingerprint

Temazepam
Cimetidine
Plasmas
Histamine H2 Receptors
Pharmacokinetics
Hypnotics and Sedatives
Benzodiazepines
Half-Life
Volunteers
Kinetics
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Drug Discovery
  • Organic Chemistry
  • Chemistry(all)
  • Molecular Medicine
  • Pharmacology
  • Pharmaceutical Science

Cite this

Greenblatt, D. J., Abernethy, D. R., Divoll, M., Locniskar, A., Harmatz, J. S., & Shader, R. I. (1984). Noninteraction of temazepam and cimetidine. Journal of Pharmaceutical Sciences, 73(3), 399-401. https://doi.org/10.1002/jps.2600730329

Noninteraction of temazepam and cimetidine. / Greenblatt, D. J.; Abernethy, D. R.; Divoll, M.; Locniskar, A.; Harmatz, J. S.; Shader, R. I.

In: Journal of Pharmaceutical Sciences, Vol. 73, No. 3, 1984, p. 399-401.

Research output: Contribution to journalArticle

Greenblatt, DJ, Abernethy, DR, Divoll, M, Locniskar, A, Harmatz, JS & Shader, RI 1984, 'Noninteraction of temazepam and cimetidine', Journal of Pharmaceutical Sciences, vol. 73, no. 3, pp. 399-401. https://doi.org/10.1002/jps.2600730329
Greenblatt DJ, Abernethy DR, Divoll M, Locniskar A, Harmatz JS, Shader RI. Noninteraction of temazepam and cimetidine. Journal of Pharmaceutical Sciences. 1984;73(3):399-401. https://doi.org/10.1002/jps.2600730329
Greenblatt, D. J. ; Abernethy, D. R. ; Divoll, M. ; Locniskar, A. ; Harmatz, J. S. ; Shader, R. I. / Noninteraction of temazepam and cimetidine. In: Journal of Pharmaceutical Sciences. 1984 ; Vol. 73, No. 3. pp. 399-401.
@article{935c2a38cbd242ec9200b4ae0e48bd12,
title = "Noninteraction of temazepam and cimetidine",
abstract = "The possible kinetic interaction of the hypnotic temazepam and the H2-receptor antagonist cimetidine was evaluated. Nine healthy male and female volunteers received a 30-mg oral dose of temazepam on two occasions in random sequence, separated by at least 1 week. On one occasion, temazepam was given in the otherwise drug-free state; on the other, temazepam was given with concurrent administration of cimetidine, 300 mg every 6 h. Mean pharmacokinetic parameters for temazepam in control versus cimetidine trials were: peak plasma concentration, 560 versus 498 ng/mL; time of peak concentration, 2.0 versus 2.1 h after the dose; volume of distribution, 1.30 versus 1.39 L/kg; elimination half-life, 9.9 versus 11.4 h; total clearance, 1.59 versus 1.60 mL/min/kg; free fraction of temazepam in plasma, 4.1 versus 3.8{\%} unbound. Cimetidine has been shown to reduce the metabolic clearance of the benzodiazepines that are biotransformed by oxidative mechanisms. Temazepam, transformed by conjugation, appears unaffected by the coadministration of cimetidine.",
author = "Greenblatt, {D. J.} and Abernethy, {D. R.} and M. Divoll and A. Locniskar and Harmatz, {J. S.} and Shader, {R. I.}",
year = "1984",
doi = "10.1002/jps.2600730329",
language = "English (US)",
volume = "73",
pages = "399--401",
journal = "Journal of Pharmaceutical Sciences",
issn = "0022-3549",
publisher = "John Wiley and Sons Inc.",
number = "3",

}

TY - JOUR

T1 - Noninteraction of temazepam and cimetidine

AU - Greenblatt, D. J.

AU - Abernethy, D. R.

AU - Divoll, M.

AU - Locniskar, A.

AU - Harmatz, J. S.

AU - Shader, R. I.

PY - 1984

Y1 - 1984

N2 - The possible kinetic interaction of the hypnotic temazepam and the H2-receptor antagonist cimetidine was evaluated. Nine healthy male and female volunteers received a 30-mg oral dose of temazepam on two occasions in random sequence, separated by at least 1 week. On one occasion, temazepam was given in the otherwise drug-free state; on the other, temazepam was given with concurrent administration of cimetidine, 300 mg every 6 h. Mean pharmacokinetic parameters for temazepam in control versus cimetidine trials were: peak plasma concentration, 560 versus 498 ng/mL; time of peak concentration, 2.0 versus 2.1 h after the dose; volume of distribution, 1.30 versus 1.39 L/kg; elimination half-life, 9.9 versus 11.4 h; total clearance, 1.59 versus 1.60 mL/min/kg; free fraction of temazepam in plasma, 4.1 versus 3.8% unbound. Cimetidine has been shown to reduce the metabolic clearance of the benzodiazepines that are biotransformed by oxidative mechanisms. Temazepam, transformed by conjugation, appears unaffected by the coadministration of cimetidine.

AB - The possible kinetic interaction of the hypnotic temazepam and the H2-receptor antagonist cimetidine was evaluated. Nine healthy male and female volunteers received a 30-mg oral dose of temazepam on two occasions in random sequence, separated by at least 1 week. On one occasion, temazepam was given in the otherwise drug-free state; on the other, temazepam was given with concurrent administration of cimetidine, 300 mg every 6 h. Mean pharmacokinetic parameters for temazepam in control versus cimetidine trials were: peak plasma concentration, 560 versus 498 ng/mL; time of peak concentration, 2.0 versus 2.1 h after the dose; volume of distribution, 1.30 versus 1.39 L/kg; elimination half-life, 9.9 versus 11.4 h; total clearance, 1.59 versus 1.60 mL/min/kg; free fraction of temazepam in plasma, 4.1 versus 3.8% unbound. Cimetidine has been shown to reduce the metabolic clearance of the benzodiazepines that are biotransformed by oxidative mechanisms. Temazepam, transformed by conjugation, appears unaffected by the coadministration of cimetidine.

UR - http://www.scopus.com/inward/record.url?scp=0021364624&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021364624&partnerID=8YFLogxK

U2 - 10.1002/jps.2600730329

DO - 10.1002/jps.2600730329

M3 - Article

C2 - 6143815

AN - SCOPUS:0021364624

VL - 73

SP - 399

EP - 401

JO - Journal of Pharmaceutical Sciences

JF - Journal of Pharmaceutical Sciences

SN - 0022-3549

IS - 3

ER -